Zai Lab Limited
再鼎醫藥有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9688)

INSIDE INFORMATION

THE INCLUSION OF VYVGART® (EFGARTIGIMOD ALFA INJECTION) IN CHINA'S NATIONAL REIMBURSEMENT DRUG LIST

This announcement is issued by Zai Lab Limited (the "**Company**") pursuant to Rule 13.09 of the Rules Governing the Listing of the Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors (the "**Board**") of the Company is pleased to announce that the 2023 National Reimbursement Drug List (the "**NRDL**") released by China's National Healthcare Security Administration has been updated to include VYVGART® (efgartigimod alfa injection) ("**VYVGART**"). VYVGART is included for the first time in the NRDL for the treatment of adult patients with generalized myasthenia gravis ("**gMG**") who are anti-acetylcholine receptor ("**AChR**") antibody positive. Including VYVGART, the Company currently has a total of four products included in the NRDL.

Myasthenia gravis is a chronic autoimmune disease, characterized by debilitating and potentially life-threatening muscle weakness. There are approximately 170,000 people in China living with gMG[1], and of those patients, 85% are estimated to have confirmed AChR antibodies; in this generalized form of the disease, skeletal muscles throughout the body may be affected, resulting in weakness and early fatigue. Difficulties with double vision, facial expression, speech, swallowing, and ambulation are frequent and difficult to manage for patients and treating physicians. In more life-threatening cases, gMG can affect the muscles responsible for breathing, which can be fatal. Acetylcholinesterase inhibitors, steroids, immunosuppressants, and IVIg are the mainstay of treatment in China. These drugs often achieve only partial restoration of strength.

VYVGART is an antibody fragment designed to reduce disease-causing immunoglobulin G ("**IgG**") antibodies and block the IgG recycling process. Efgartigimod binds to the neonatal Fc receptor ("**FcRn**"), which is widely expressed throughout the body and plays a central role in rescuing IgG antibodies from degradation. The National Medical Products Administration approved VYVGART as an add on to standard

[1] The growing burden of generalized myasthenia gravis: a population-based retrospective cohort study in Taiwan, 2023.

therapy for the treatment of adult patients with gMG who are anti-AChR antibody positive in June 2023. VYVGART is the first approved FcRn blocker in China.

The Company commercially launched VYVGART in mainland China in September 2023. The Company has an exclusive license from argenx to develop and commercialize efgartigimod in mainland China, Hong Kong, Macau, and Taiwan.

By order of the Board
Zai Lab Limited
Samantha Du
Director, Chairperson and Chief Executive Officer

Hong Kong, December 13, 2023

As at the date of this announcement, the board of directors of the Company comprises Dr. Samantha Du as a director, and Dr. Kai-Xian Chen, Dr. John Diekman, Richard Gaynor, M.D., Ms. Nisa Leung, Mr. William Lis, Mr. Scott W. Morrison, Mr. Leon O. Moulder, Jr., Mr. Michel Vounatsos and Mr. Peter Wirth as independent directors.

** For identification only*